Araştırma Makalesi

Transcranial direct current stimulation ameliorates motor and cognitive functions by regulating neuronal excitotoxicity in experimental Parkinson’s disease model

Cilt: 48 Sayı: 3 30 Eylül 2023
Güven Akçay *, Serhan Tamerer
PDF İndir
EN TR

Transcranial direct current stimulation ameliorates motor and cognitive functions by regulating neuronal excitotoxicity in experimental Parkinson’s disease model

Abstract

Purpose: In the study, the therapeutic effects of early and long-term transcranial direct current stimulation (tDCS) in Parkinson's disease (PD) rats with 6-hydroxydopamine (6-OHDA) lesions of tDCS were investigated. Materials and Methods: After early and prolonged tDCS administration in PD animals (starting 24 hours after PD lesion, 1000 mA anodal tDCS, 30 min/day, 13 days), the effects of tDCS on motor and cognitive function behaviors and glutamatergic neuron excitotoxicity were determined by Ca2+, glutamate, and NMDAR1 levels. Results: We found that the 13-day tDCS intervention significantly reduced 6-OHDA-induced motor deficits in locomotor activity, learning, and memory-like behavior. Biochemically, we showed that it also reduces Ca2+, glutamate, and NMDAR1 levels, which cause hippocampal neuronal damage. Conclusion: These results suggest that early and long-term tDCS may exert neuroprotective effects and reduce the exacerbation of motor and cognitive impairments in a rat model of 6-OHDA-induced PD. However, it also shows that tDCS has an effect on the glutamatergic pathway in PD and prevents neuronal excitotoxicity. Furthermore, this preclinical model may increase the potential use of therapeutic tDCS and serve as a translation platform to further define the therapeutic mechanism of tDCS for PD or other disorders.

Keywords

Learning , Locomotor Activity , Neuroprotective Treatment , Parkinson , Transcranial Direct Current Stimulation

Kaynakça

  1. Foffani G, Obeso JA. A cortical pathogenic theory of Parkinson’s disease. Neuron. 2018;99:1116-28.
  2. Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18:101-13.
  3. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry. 2005;13:844-51.
  4. Chen JJ, Swope DM. Pharmacotherapy for Parkinson's disease. Pharmacotherapy. 2007;27:161-73.
  5. Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. The FASEB journal. 2003;17:1-18.
  6. Casetta I, Govoni V, Granieri E. Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Des.. 2005;11:2033-52.
  7. Dipasquale B, Marini AM, Youle RJ. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem Biophys Res Commun. 1991;181:1442-8.
  8. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 2007;69:1836-42.
  9. Yıgıt G, Arıcıoglu F. Günümüz ve gelecekte Parkinson Hastalığı için farmakolojik Tedavi yaklaşımları. Clinical and Experimental Health Sciences. 2015;5:265-73.
  10. Nakanishi S, Masu M. Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct. 1994;23:319-48.

Kaynak Göster

MLA
Akçay, Güven, ve Serhan Tamerer. “Transcranial direct current stimulation ameliorates motor and cognitive functions by regulating neuronal excitotoxicity in experimental Parkinson’s disease model”. Cukurova Medical Journal, c. 48, sy 3, Eylül 2023, ss. 919-28, doi:10.17826/cumj.1322361.